Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer
NCT05328440Phase 2Active, not recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, pyrotinib in breast cancer, sponsored by Henan Cancer Hospital. Started May 2022; status: active, not recruiting.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05328440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328440.